Health Sciences Acquisitions Co. 2 (HSAQ) Competitors $6.07 +0.41 (+7.24%) (As of 11/13/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends HSAQ vs. SRDX, TMCI, CVRX, TCMD, CERS, RCEL, OSUR, CLPT, LUNG, and ANGOShould you be buying Health Sciences Acquisitions Co. 2 stock or one of its competitors? The main competitors of Health Sciences Acquisitions Co. 2 include Surmodics (SRDX), Treace Medical Concepts (TMCI), CVRx (CVRX), Tactile Systems Technology (TCMD), Cerus (CERS), AVITA Medical (RCEL), OraSure Technologies (OSUR), ClearPoint Neuro (CLPT), Pulmonx (LUNG), and AngioDynamics (ANGO). These companies are all part of the "surgical & medical instruments" industry. Health Sciences Acquisitions Co. 2 vs. Surmodics Treace Medical Concepts CVRx Tactile Systems Technology Cerus AVITA Medical OraSure Technologies ClearPoint Neuro Pulmonx AngioDynamics Surmodics (NASDAQ:SRDX) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, community ranking, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Does the MarketBeat Community believe in SRDX or HSAQ? Surmodics received 337 more outperform votes than Health Sciences Acquisitions Co. 2 when rated by MarketBeat users. CompanyUnderperformOutperformSurmodicsOutperform Votes33763.71% Underperform Votes19236.29% Health Sciences Acquisitions Co. 2N/AN/A Do analysts prefer SRDX or HSAQ? Surmodics currently has a consensus target price of $50.00, suggesting a potential upside of 31.03%. Given Surmodics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Surmodics is more favorable than Health Sciences Acquisitions Co. 2.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Surmodics 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Health Sciences Acquisitions Co. 2 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor SRDX or HSAQ? In the previous week, Surmodics had 11 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 12 mentions for Surmodics and 1 mentions for Health Sciences Acquisitions Co. 2. Surmodics' average media sentiment score of 1.04 beat Health Sciences Acquisitions Co. 2's score of 0.16 indicating that Surmodics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surmodics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Health Sciences Acquisitions Co. 2 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SRDX or HSAQ more profitable? Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Surmodics' net margin of -9.15%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Surmodics' return on equity.Company Net Margins Return on Equity Return on Assets Surmodics-9.15% -3.77% -2.54% Health Sciences Acquisitions Co. 2 N/A N/A -2.38% Which has more risk and volatility, SRDX or HSAQ? Surmodics has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Do institutionals and insiders hold more shares of SRDX or HSAQ? 96.6% of Surmodics shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 8.9% of Surmodics shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has better earnings and valuation, SRDX or HSAQ? Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Surmodics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurmodics$126.08M4.32-$11.54M-$0.81-47.11Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A SummarySurmodics beats Health Sciences Acquisitions Co. 2 on 8 of the 13 factors compared between the two stocks. Ad Crypto 101 MediaDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HSAQ vs. The Competition Export to ExcelMetricHealth Sciences Acquisitions Co. 2Surgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.06M$4.63B$5.33B$8.91BDividend YieldN/A39.52%4.98%4.03%P/E RatioN/A25.10135.4417.46Price / SalesN/A63.901,266.8895.47Price / CashN/A52.4438.8936.42Price / Book-9.795.596.315.92Net Income-$380,000.00$13.58M$118.33M$224.86M7 Day Performance-4.56%-1.04%-1.43%-0.38%1 Month Performance-54.40%6.33%3.12%4.21%1 Year Performance0.50%55.17%36.57%27.31% Health Sciences Acquisitions Co. 2 Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HSAQHealth Sciences Acquisitions Co. 2N/A$6.07+7.2%N/A+0.5%$68.06MN/A0.004Gap UpSRDXSurmodics4.3582 of 5 stars$38.48+0.1%N/A+18.0%$548.99M$126.08M-47.51376Analyst RevisionPositive NewsTMCITreace Medical Concepts1.2079 of 5 stars$8.29+3.1%N/A+31.3%$516.44M$202.86M-8.37250Gap DownCVRXCVRx3.1017 of 5 stars$15.83+2.0%N/A-20.3%$384.04M$39.29M-5.86200Positive NewsTCMDTactile Systems Technology3.9464 of 5 stars$15.96+6.3%N/A+50.9%$383.04M$274.42M24.55980CERSCerus2.928 of 5 stars$2.03+14.0%N/A+17.7%$376.99M$156.37M-18.45625Short Interest ↑High Trading VolumeRCELAVITA Medical1.9588 of 5 stars$12.20+2.1%N/A+3.0%$317.08M$50.14M-5.47130Earnings ReportGap DownOSUROraSure Technologies4.6155 of 5 stars$4.24-1.2%N/A-38.1%$316.26M$405.47M28.27638CLPTClearPoint Neuro0.9917 of 5 stars$11.41-2.1%N/A+139.6%$314.87M$28.07M-16.54110Analyst RevisionGap UpLUNGPulmonx3.6141 of 5 stars$7.55+1.5%N/A-32.9%$298.15M$68.68M-5.14250Short Interest ↓ANGOAngioDynamics4.7622 of 5 stars$7.44+3.3%N/A+9.2%$292.57M$292.73M-1.22748Short Interest ↓Positive News Related Companies and Tools Related Companies Surmodics Competitors Treace Medical Concepts Competitors CVRx Competitors Tactile Systems Technology Competitors Cerus Competitors AVITA Medical Competitors OraSure Technologies Competitors ClearPoint Neuro Competitors Pulmonx Competitors AngioDynamics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HSAQ) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopp...Golden Crest | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Health Sciences Acquisitions Co. 2 Please log in to your account or sign up in order to add this asset to your watchlist. Share Health Sciences Acquisitions Co. 2 With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
